Señales en vivo de ALPHA.PA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 11:35):

Stats
Volumen de hoy	329 806
Volumen promedio	40 149.00
Capitalización de mercado	60 019.00
EPS	€0 ( 2024-04-19 )
Próxima fecha de ganancias	( €0 ) 2024-05-07
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	0
ATR14	€0.00300 (3.05%)

Volumen Correlación

Largo: -0.19 (neutral)

Corto: -0.52 (weak negative)

Signal:(45.963) Neutral

Pharnext SA Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharnext SA Correlación - Moneda/Commodity

-0.40
( neutral )

0.16
( neutral )

0.00
( neutral )

-0.55
( weak negative )

Pharnext SA Finanzas

Annual	2022
Ingresos:	€558.00
Beneficio Bruto:	€2.26M (404 643.19 %)
EPS:	€-8.32

FY	2022
Ingresos:	€558.00
Beneficio Bruto:	€2.26M (404 643.19 %)
EPS:	€-8.32

FY	2021
Ingresos:	€84 785.00
Beneficio Bruto:	€0.00 (0.00 %)
EPS:	€-5 033.08

FY	2020
Ingresos:	€39 830.00
Beneficio Bruto:	€-284 720 (-714.84 %)
EPS:	€-5 920.66

Financial Reports:

No articles found.

Pharnext SA

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.

Actualizaciones en tiempo real para Pharnext SA [ALPHA.PA]

Upcoming Earnings Alert